देश: दक्षिण अफ़्रीका
भाषा: अंग्रेज़ी
स्रोत: South African Health Products Regulatory Authority (SAHPRA)
Aspen-p
ASPEN ZIDOVUDINE 100 MG (CAPSULE) ASPEN ZIDOVUDINE 250 MG (CAPSULE) SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): ASPEN ZIDOVUDINE 100 MG (CAPSULE) ASPEN ZIDOVUDINE 250 MG (CAPSULE) COMPOSITION: Each ASPEN ZIDOVUDINE 100 MG capsule contains zidovudine 100 mg. Each ASPEN ZIDOVUDINE 250 MG capsule contains zidovudine 250 mg. PHARMACOLOGICAL CLASSIFICATION: A.20.2.8 Antiviral agents PHARMACOLOGICAL ACTION: Zidovudine, a thymidine nucleoside analogue, is an antiviral medicine with in vitro activity against retroviruses, such as the Human Immunodeficiency Virus (HIV) and the Human T lymphotropic virus (HTLV) I. Following diffusion into both infected and uninfected host cells, zidovudine is phosphorylated to the monophosphate derivative by cellular thymidine kinase. The phosphorylation of zidovudine-monophosphate to the diphosphate derivative and to the zidovudine-triphosphate is in turn catalysed by cellular thymidylate kinase and unspecific kinases, respectively. Zidovudine-triphosphate is a competitive inhibitor of, and a substrate for, reverse transcriptase with respect to the thymidine triphosphate (TTP) nucleotide. The incorporation of zidovudine-triphosphate into the proviral DNA chain blocks further chain formation and results in chain termination. Zidovudine-triphosphate has greater affinity (approximately 100-fold) for HIV reverse transcriptase than for human DNA polymerase alpha. Combination therapy with lamivudine: Zidovudine monotherapy leads to development of in vitro and in vivo resistance to zidovudine. Zidovudine has been shown to act additively or synergistically with other anti-HIV agents, inhibiting the replication of HIV in cell culture. Additive or synergistic activity in cell culture has been demonstrated in medicine combination studies of zidovudine with पूरा दस्तावेज़ पढ़ें